Iron-mediated cardiovascular injury

Abstract

Iron is an essential element for normal cellular function and general health. However, iron may play a pathologic role in certain cardiac conditions including reperfusion injury, hemochromatosis, b-thalassemia and coronary atherosclerosis. It also may play a role in injury due to anthracycline cardiotoxicity. Removal of iron via phlebotomy for hemochromatosis and chelation therapy for b-thalassemia are proven treatments. Cell culture, and isolated organ and animal studies suggest that depleting iron stores may prevent reperfusion injury, restenosis and even atherogenesis. This article will review mechanisms by which iron overload states and normal iron stores contribute to cardiovascular pathophysiology and the accumulating evidence that iron chelation may prevent restenosis and atherogenesis.

Keywords

free radicals iron and atherosclerosis iron overload reperfusion injury

References

Hearse DJ , Humphrey SM , Nayler WG , Slade A , Border D. Ultra-structural damage associated with reoxygenation of the anoxic myocardium. J Mol Cell Cardiol 1975; 7: 315-324.

Horwitz LD , Fennessey PV , Shikes RH , Kong Y. Marked reduction in myocardial infarct size due to prolonged infusion of an antioxidant during reperfusion. Circulation 1994; 89: 1792-1801.

Connolly ES Jr , Winfree CJ , Springer TA et al. Cerebral protection in homozygous null Icam-1 mice after middle cerebral artery occlusion: role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 1996; 97: 209-216.

McCord JM. Oxygen-derived free radicals in post-ischemic tissue injury. N Engl J Med 1985; 312: 159-163.

Boveris A , Chance B. The mitochondrial generation of hydrogen peroxide: general properties and effect of hyperbaric oxygen. Biochem J 1973; 134: 707-716.

Horwitz LD , Leff JA. Catalase and hydrogen peroxide cytotoxicity in cultured cardiac myocytes. J Mol Cell Cardiol 1995; 27: 909-915.

Floyd RA , Lewis CA. Hydroxyl free radical formation from hydrogen peroxide by ferrous iron-nucleotide complexes. Biochemistry 1983; 22: 2645-2649.

Graf E , Mahoney JR , Bryant RG , Eaton JW. Iron-catalyzed hydroxyl formation. J Biol Chem 1984; 259: 3620-3624.

Lesnefsky EJ , Ye J. Exogenous intracellular, but not extracellular, iron augments myocardial reperfusion injury. Am J Physiol 1994; 266: H384-H392.

10.

Voogd A , Sluiter, Koster JF. The increased susceptibility to hydrogen peroxide of the (post-)ischemic rat heart is associated with the magnitude of the low molecular weight iron pool. Free Radic Biol Med 1994; 16: 453-458.

11.

Byler RM , Sherman NA , Wallner JS , Horwitz LD. Hydrogen peroxide cytotoxicity in cultured cardiac myocytes is iron dependent. Am J Physiol 1994; 266: H121-H127.

12.

Lesnefsky EJ , Dauber IM , Horwitz LD. Altered myocardial sulfhydryl pools during reperfusion in canine models of infarcted and stunned myocardium. Circ Res 1991; 68: 605-613.

13.

Farber NE , Vercellotti GM , Jacobs HS , Pieper GM , Gross GJ. Evidence for a role of iron-catalyzed oxidants in functional and metabolic stunning in the canine heart. Circ Res 1988; 63: 351-360.

14.

Williams RE , Zweier JL , Flaherty JT. Treatment with deferoxamine during ischemia improves functional and metabolic recovery and reduces reperfusion-induced oxygen radical generation in rabbit hearts. Circulation 1991; 83: 1006-1014.

15.

Reddy BR , Kloner RA , Przyklenk K. Early treatment with deferoxamine limits myocardial ischemia/reperfusion injury. Free Radic Biol Med 1989; 7: 45-52.

16.

Lesnefsky EJ , Repine JE , Horwitz LD. Deferoxamine pretreatment reduces canine infarct size and oxidative injury. J Pharmacol Exp Ther 1990; 253: 1103-1109.

17.

Summers MR , Jacobs A , Tudway B , Perera P , Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 1979; 42: 547-555.

18.

Lloyd JB , Cable H , Rice-Evans C. Evidence that desferrioxamine cannot enter cells by passive diffusion. Biochem Pharmacol 1991; 41: 1361-1363.

19.

Gobin J , Moore CH , Reeve JR Jr , Wong DK , Gibson BW , Horwitz MA. Iron acquisition by Mycobacterium tuberculosis: isolation and characterization of a family of iron-binding exochelins. Proc Natl Acad Sci USA 1995; 92: 5189-5193.

20.

Horwitz LD , Sherman NA , Kong Y , et al. Lipophilic siderophores of mycobacterium tuberculosis prevent cardiac reperfusion injury. Proc Natl Acad Sci USA 1998; 95: 5263-5268.

21.

Gordeuk V , Mukiibi J , Hasstedt SI et al. Iron overload in Africa: interaction between a gene and dietary iron content. N Engl J Med 1992; 326: 95-100.

22.

Pippard MJ , Wetherall DJ. Iron absorption in non-transfused iron loading anemias. Prediction of risk of iron loading, and response to iron chelation treatment in ß-thalassemia intermedia and congenital sideroblastic anemias. Haematologica 1984; 17: 404-414.

23.

Ward JH , Kushner JP , Kaplan J. Regulation of HeLa cell transferrin receptor number. J Biol Chem 1982; 257: 10 317-10 323.

24.

Munro HN , Lindner MC. Ferritin structure, biosynthesis and function. Physiol Rev 1978; 58: 317-396.

25.

Klausner R , Roualt TA , Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 1993; 72: 19-28.

26.

Olson LJ , Edwards WD , Holmes DR , Miller FA , Nordstrom LA , Baldus WP. Endomyocardial biopsy in hemochromatosis: clinicopathologic correlates in six cases. J Am Coll Cardiol 1989; 131: 116-120.

27.

Trousseau A. Glycosurie; diabete sucre. Clinique médicale ce l’Hotel-Dieu de Paris 1865; 2: 663-98.

28.

Feder JN , Gnirk A , Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.

29.

Edwards CQ , Griffin LM , Goldyar D , Drummond C , Skolnick MH , Kusher JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355-1362.

30.

Aldouri MA , Wonke B , Hoffbrand AV et al. High incidence of cardiomyopathy in beta thalassemia patients receiving regular transfusions and iron chelation: reversal by intensified chelation. Acta Hematol 1990; 84: 113-117.

31.

Fitchett DH , Coltart DJ , Littler WA et al. Cardiac involvement in secondary hemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res 1980; 14: 719-724.

32.

Olson LJ , Edwards WD , McCall JT et al. Cardiac iron deposition from idiopathic hemochromatosis: histologic and analytical assessment of 14 hearts from autopsy. J Am Coll Cardiol 1987: 10: 1239-1243.

33.

Buja LM , Roberts WC. Iron in the heart: etiology and clinical significance. Am J Med 1971; 51: 209-221.

34.

Skinner C , Kenmure ACF. Hemochromatosis presenting as congestive cardiomyopathy and responding to venesection. Br Heart J 1973; 35: 466-468.

35.

Wasserman AJ , Richardson DW , Baird CL , Wyso EM. Cardiac hemochromatosis simulating constrictive pericarditis. Am J Med 1962; 32: 316-323.

36.

Candell-Riera J , Lu L , Serés L et al. Cardiac hemochromatosis: beneficial effects of iron removal therapy. An echocardiographic study. Am J Cardiol 1983; 52: 824-829.

37.

Dabestani A , Child JS , Henze E et al. Primary hemochromatosis: anatomic and physiologic characteristics of the cardiac ventricles and their response to phlebotomy. Am J Cardiol 1984; 54: 153-159.

38.

Waxman S , Eustace S , Hartnell GG. Myocardial involvement in primary hemochromatosis demonstrated by magnetic resonance imaging. Am Heart J 1994; 128: 1047-1049.

39.

Dover GJ , Valle D. Therapy for b-thalassemia? a paradigm for the treatment of genetic disorders. N Engl J Med 1994; 331: 609-610.

40.

Wolfe L , Olivieri N , Sallan D et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985; 312: 1600-1603.

41.

Olivieri NF , Nathan DG , MacMillan JH et al. Survival in medically treated patients with homozygous b-thalassemia. N Engl J Med 1994; 331: 574-578.

42.

Brittenham GM , Griffith PM , Nienhuis AW et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-573.

43.

Freeman AP , Giles RW , Berdoukas VA et al. Sustained normalization of cardiac function by chelation therapy in thalassemia major. Clin Lab Haematol 1989; 11: 299-307.

44.

Freeman AP , Giles RW , Berdoukas VA et al. Early left ventricular dysfunction and chelation therapy in thalassemia major. Ann Intern Med 1983; 99: 450-454.

45.

Carmine TC , Evans P , Bruchelt G et al. Presence of iron catalytic for free radical reactions in patients undergoing chemotherapy: implications for therapeutic management. Cancer Lett 1995; 94: 219-226.

46.

Powis G. Free radical formation by antitumor quinones. Free Radic Biol Med 1989; 6: 63-101.

47.

Speyer JL , Green MD , Zeleniuch-Jacquotte A et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-127.

48.

Hershko C , Link G , Pinson A. The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk Lymphoma 1993; 11: 207-214.

49.

Gordeuk VR , Brittenham GM. Bleomycin-reactive iron in patients with acute non-lymphocytic leukemia. FEBS Lett 1992; 308: 4-6.

50.

Beare S , Steward WP. Plasma free iron and chemotherapy toxicity. Lancet 1996; 347: 342-343.

51.

Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981; i: 1293-1294.

52.

Araujo JA , Romano EL , Brito BE et al. Iron overload augments the development of atherosclerotic lesions in rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 1172-1180.

53.

Van Lenten BJ , Prieve J , Navab M , Hama S , Lusis AJ , Fogelman AM. Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J Clin Invest 1995; 95: 2104-2110.

54.

Gutteridge JMC , Richmond R , Halliwell B. Inhibition of the iron-catalyzed formation of hydroxyl radicals from superoxide and of lipid peroxidation by desferrioxamine. Biochem J 1979; 184: 469-472.

55.

Lucas JJ , Szepesi A , Domenico J et al. Effects of iron depletion on cell cycle progression in normal human T lymphocytes: selective inhibition of the appearance of the cyclin A-associated component of the R33cdAz kinase. Blood 1995; 86: 2268-2280.

56.

Porreca E , Ucchino S , Di Febbo C et al. Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb 1994; 14: 299-304.

57.

Hagen PO , Davies MG , Schuman RW , Murray JJ. Reduction of vein graft intimal hyperplasia by ex vivo treatment with desferrioxamine manganese. J Vasc Res 1992; 29: 405-409.

58.

Pang J-HS , Jiang M-J , Chen Y-L et al. Increased ferritin gene expression in atherosclerotic lesions. J Clin Invest 1996; 97: 2204-2212.

59.

Salonen JT , Nyyssonen K , Korpela H , Tuomilehto J , Seppanen R , Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86: 803-811.

60.

Berge LN , Bonaa KH , Norday A. Serum ferritin, sex hormones, and cardiovascular risk factors in healthy women. Arterioscler Thromb 1994; 14: 857-861.

61.

Kiechl S , Willeit J , Egger G , Poewe W , Oberhollenzer F. Body iron stores and the risk of carotid arteriosclerosis: prospective results from the Bruneck study. Circulation 1997; 96: 3300-3307.

62.

Magnusson MK , Sigfusson N , Sigvaldason H et al. Low iron binding capacity as a risk factor for myocardial infarction. Circulation 1994; 89: 102-108.

63.

Rauramaa R , Vaisanen S , Mercuri M et al. Association of risk factors and body iron status to carotid atherosclerosis in middle-aged eastern Finnish men. Eur Heart J 1994; 15: 1020-1027.

64.

Moore M , Folsom AR , Barnes RW et al. No association between serum ferritin and asymptomatic carotid atherosclerosis. Am J Epidemiol 1995; 141: 719-723.

65.

Baer DM , Tekawa IS , Hurley LB. Iron stores are not associated with acute myocardial infarction. Circulation 1994; 89: 2915-2918.

66.

Morrison HI , Semenciw RM , Mao Y. Serum iron and risk of fatal acute myocardial infarction. Epidemiology 1994; 5: 243-246.

67.

Ascherio A , Willett WC , Rimm EB. Dietary iron intake and risk of coronary artery disease among men. Circulation 1994; 89: 969-974.

68.

Reunanen A , Takkunen H , Knekt P et al. Body iron stores, dietary iron intake and coronary heart disease mortality. J Intern Med 1995; 238: 223-230.